Other Events ·
BioCryst Pharmaceuticals, Inc. approved a plan to discontinue its internal discovery programs and close its Discovery…
BCRXBiocryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc. approved a plan to discontinue its internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama, as part of a strategic evolution to focus on rare disease pipeline. The implementation of the Plan is expected to be substantially complete by the end of 2026. The company is currently unable to estimate the total costs associated with the following: contract termination, lease termination, employee termination benefits, and severance. BioCryst Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes drugs for rare diseases.